Trial Profile
A cross-sectional study assessing the prevalence of critical COVID-19 disease among post-vaccinated patients in a tertiary hospital in the Philippines
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; BBV 152 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 22 Jul 2022 New trial record